All In Biotech

NDA 019962 · Melinta Therap

Toprol-Xl

Metoprolol Succinate · Oral

Last checked: Nov 20, 2026Latest source record: Mar 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Jan 10, 1992

Approved uses

4

Original approval plus efficacy supplements

Registered trials

302

56 Phase 3, 19 recruiting

FAERS reports

88,225

54,921 serious, 8,049 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 3, 2026.

TOPROL-XL, metoprolol succinate, is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure ( 1.3 ) 1.1 Hypertension TOPROL-XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular...

Mechanism: Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. The relative beta 1...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • TOPROL-XL · METOPROLOL SUCCINATE EQ 200MG TARTRATE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • TOPROL-XL · METOPROLOL SUCCINATE EQ 50MG TARTRATE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • TOPROL-XL · METOPROLOL SUCCINATE EQ 25MG TARTRATE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • TOPROL-XL · METOPROLOL SUCCINATE EQ 100MG TARTRATE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Metoprolol" as an intervention, any sponsor and status, largest first.

All 302 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue6,628
  • diarrhoea5,434
  • nausea5,124
  • dyspnoea5,068
  • drug ineffective4,420
  • dizziness4,356
  • off label use4,331
  • headache4,004
  • death3,608
  • asthenia3,350
  • pain3,286
  • fall3,171

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004589
2005538
2006696
20071,529
2008890
20091,252
2010983
20111,876
20123,087
20131,535
20144,012
20155,011
20165,332
20175,626
20186,458
20196,109
20205,687
20215,015
20225,570
20235,880
20246,865
20257,767
20265,916

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Toprol XL (Metoprolol Succinate)

2024 spending

$5.0M

Beneficiaries

9,214

37,862 claims

Per beneficiary

$541

$1.45 per unit

View as table
YearSpending
2020$10,797,699
2021$7,097,353
2022$6,403,263
2023$5,726,668
2024$4,983,198

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,995 on PubMed

Sponsor: Melinta Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.